Biozona Weekly: TGen study; Tucson ALS clinic; UA tech park

September 5, 2014

By hammersmith

TGen begins cutting-edge brain cancer treatment trials
9/2/14 | Independent Newsmedia | Staff Report

Translational Genomics Research Institute and its clinical partners have received final regulatory approval for a groundbreaking brain cancer research trial to test promising new drugs that might extend the survival of Glioblastoma patients.

Tucson ALS clinic, research lab of fruit flies help Southern Arizona patients
9/2/14 | Tucson News Now | Jackie Kent

The ALS Clinic at the University of Arizona South Campus is working with a research lab at the UA that’s trying to break down the components of the disease–by studying fruit flies.

Streamlined permitting process stokes Phoenix development
8/31/14 | Arizona Republic | Betty Reid

The 10-story Biosciences Partnership Building and an 8-story parking garage, both planned for the Phoenix Biomedical Campus in downtown Phoenix, are two of the city’s future major development projects.

UA refocuses tech-park strategy
8/31/14 | Arizona Daily Star | David Wichner

The University of Arizona’s technology park is nearing its 20th anniversary with a new strategy focusing on more active recruitment of firms eager to collaborate with the UA, part of an ongoing overhaul under Tech Launch Arizona, the UA’s technology commercialization arm.

UA Health Network answers questions about Banner deal

8/31/14 | Arizona Daily Star | Stephanie Innes

The Arizona Daily Star sat down with Joe G.N. “Skip” Garcia, vice president of health sciences at the University of Arizona, a member of the UA Health Network Board of Directors and interim dean of the UA College of Medicine-Tucson, to get some answers about the UA deal with Banner Health.

Ventana Medical Systems to open new distribution facility
8/28/14 | Arizona Public Media | Zachary Ziegler

Ventana Medical Systems will sign on as lessee in a new business park in Marana, moving its distribution operations from near Tucson International Airport to a custom-built, 60,000-square-foot facility just west of Interstate 10.

New treatments provide hope for children with Spinal Muscular Atrophy
8/28/14 | Arizona Republic | TGen (Submitted)

Lisa Baumbach-Reardon, a neurogenomics investigator at TGen, believes there is hope for those who suffer from Spinal Muscular Atrophy, a rare, debilitating and usually deadly disease that strikes children in infancy.